{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:55:53Z","timestamp":1793890553100,"version":"4.8.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Cedars-Sinai Medical Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40265-023-01840-5","type":"journal-article","created":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T01:03:30Z","timestamp":1679187810000},"page":"299-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3727-1851","authenticated-orcid":false,"given":"Paulina","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-0526","authenticated-orcid":false,"given":"Rodrigo","family":"Quera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-5555","authenticated-orcid":false,"given":"Andres J.","family":"Yarur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"1840_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/ajg.2008.88","volume":"104","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review. Am J Gastroenterol. 2009;104:760\u20137. https:\/\/doi.org\/10.1038\/ajg.2008.88.","journal-title":"Am J Gastroenterol"},{"key":"1840_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","volume":"52","author":"Y Qiu","year":"2017","unstructured":"Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNF alpha dose intensification in Crohn\u2019s disease. J Gastroenterol. 2017;52:535\u201354. https:\/\/doi.org\/10.1007\/s00535-017-1324-3.","journal-title":"J Gastroenterol"},{"issue":"9","key":"1840_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","volume":"14","author":"D Gilardi","year":"2020","unstructured":"Gilardi D, Gabbiadini R, Alloca M, Correale C, Fiorino G, Furfaro F, et al. PK, PD and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecules drugs in IBD. Expert Rev Gastroenterol Hepatol. 2020;14(9):797\u2013806. https:\/\/doi.org\/10.1080\/17474124.2020.1785868.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1840_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/312912","volume":"66","author":"P Olivera","year":"2017","unstructured":"Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199\u2013209. https:\/\/doi.org\/10.1136\/312912.","journal-title":"Gut"},{"key":"1840_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","volume":"11","author":"LCS De Vries","year":"2017","unstructured":"De Vries LCS, Wildenberg ME, De Jonge WJ, D\u2019Haenes GR. The future of Janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2017;11:885\u201393. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx003.","journal-title":"J Crohns Colitis"},{"key":"1840_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/1744666X.2017.1291342","volume":"13","author":"P Olivera","year":"2017","unstructured":"Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:693\u2013703. https:\/\/doi.org\/10.1080\/1744666X.2017.1291342.","journal-title":"Expert Rev Clin Immunol"},{"key":"1840_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate responde inhibitors. N Engl J Med. 2017;377:1525\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1615977.","journal-title":"N Engl J Med"},{"key":"1840_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, ORAL Solo Investigators, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109071.","journal-title":"N Engl J Med"},{"key":"1840_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13075-015-0825-9","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Kremer J, Wallenstein G, Kanit KS, Connell C, Gruben D, et al. Effects of tofacitinib monotherapy op patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther. 2015;17:307. https:\/\/doi.org\/10.1186\/s13075-015-0825-9.","journal-title":"Arthritis Res Ther"},{"key":"1840_CR10","unstructured":"Drugs.com FDA approves Xeljanz for rheumatoid arthritis. https:\/\/www.drugs.com\/newdrugs\/fda-approvesxeljanz-rheumatoid-arthritis-3558.html. Published November 6, 2012. Accessed 10 Feb 2022."},{"key":"1840_CR11","unstructured":"Drugs.com Pfizer announces FDA approval of Xeljanz (tofacitinib) and Xel- janz XR for the treatment of active psoriatic arthritis. https:\/\/www.drugs.com\/newdrugs\/pfizer-announces-fda-approval-xeljanz-tofacitinib-xeljanz-xr-active-pso-riatic-arthritis-4677.html. Published December 14, 2017. Accessed 10 Feb 2022."},{"key":"1840_CR12","unstructured":"Drugs.com FDA approves Xeljanz for active ankylosing spondylitis. https:\/\/www.drugs.com\/newdrugs\/u-s-fda-approves-pfizer-s-xeljanz-tofacitinib-active-ankylosing-spondylitis-5734.html Published December 14, 2021. Accessed 10 Feb 2022."},{"issue":"Suppl 3","key":"1840_CR13","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1007\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, IBD guidelines eDelphi Consensus Group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106. https:\/\/doi.org\/10.1007\/gutjnl-2019-318484.","journal-title":"Gut"},{"key":"1840_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell M, for the Study A3921063 investigators, et al. Tofacitinib, an oral janus kinase inhibitor in active ulcerative colitis. N Engl J Med. 2012;367:616\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1112168.","journal-title":"N Engl J Med"},{"key":"1840_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","volume":"12","author":"J Pan\u00e9s","year":"2018","unstructured":"Pan\u00e9s J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, et al. Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomized controlled induction and maintenance studies. J Crohns Colitis. 2018;12:145\u201356. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx133.","journal-title":"J Crohns Colitis"},{"key":"1840_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"N Engl J Med"},{"issue":"2","key":"1840_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/apt.15555","volume":"51","author":"BE Sands","year":"2020","unstructured":"Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2020;51(2):271\u201380. https:\/\/doi.org\/10.1111\/apt.15555.","journal-title":"Aliment Pharmacol Ther"},{"key":"1840_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.029","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014. https:\/\/doi.org\/10.1016\/j.cgh.2014.01.029.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1840_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D\u2019Haens G, et al. Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomized placebo-controlled trials. Gut. 2017;66:1049\u201359. https:\/\/doi.org\/10.1136\/gutjnl-2016-312735.","journal-title":"Gut"},{"key":"1840_CR20","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-11-4","author":"E Liu","year":"2022","unstructured":"Liu E, Aslam N, Nigam G, Limdi JK. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease\u2014where we are and where we are going. Drugs Context. 2022. https:\/\/doi.org\/10.7573\/dic.2021-11-4.","journal-title":"Drugs Context"},{"key":"1840_CR21","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.cgh.2020.10.025","volume":"19","author":"M Fenster","year":"2021","unstructured":"Fenster M, Alayo QA, Khatiwada A, Wang W, Dimopoulos C, Gutierrez A, et al. Real-world effectiveness and safety of tofacitinib in Crohn\u2019s disease and IBD-U: a multicenter study from the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021;19:2207\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.025.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1840_CR22","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","volume":"14","author":"S Honap","year":"2020","unstructured":"Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicenter UK experience. J Crohns Colitis. 2020;14(10):1385\u201393. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa075.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1840_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-World effectiveness, and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28(1):32\u201340. https:\/\/doi.org\/10.1093\/ibd\/izab011.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"1840_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","volume":"15","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15(1):35\u201342. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa145.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"1840_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.1568933","volume":"51","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, Sleutjes JAM, de Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51(9):880\u20138. https:\/\/doi.org\/10.1111\/apt.1568933.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"1840_CR26","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1093\/ecco-jcc\/jjy222.468","volume":"13","author":"R Ungaro","year":"2019","unstructured":"Ungaro R, Fenster M, Dimopoulos C, Patel A, Deepak D, Syal G, et al. P344 real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. J Crohns Colitis. 2019;13(Suppl. 1):S274\u20135. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy222.468.","journal-title":"J Crohns Colitis"},{"key":"1840_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.dld.2021.11.009","volume":"54","author":"I Avni-Biron","year":"2022","unstructured":"Avni-Biron I, Shirit A, Koslowsky B, Levartovsky A, Kopylov U, Weisshof R, et al. Short-term effectiveness and safety of tofacitinib in ulcerative colitis-real world data from tertiary medical centers in Israel. Dig Liver Dis. 2022;54:192\u20137. https:\/\/doi.org\/10.1016\/j.dld.2021.11.009. (PMID: 34887214).","journal-title":"Dig Liver Dis"},{"issue":"8","key":"1840_CR28","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sanborn","year":"2020","unstructured":"Sanborn WJ, Gosh S, Panes J, Schreiber S, D\u2019Haens G, Tanida S, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139\u201349. https:\/\/doi.org\/10.1053\/j.gastro.2020.02.030.","journal-title":"Gastroenterology"},{"issue":"10341","key":"1840_CR29","doi-asserted-by":"publisher","first-page":"21132128","DOI":"10.1016\/SO140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomized trial. Lancet. 2022;399(10341):21132128. https:\/\/doi.org\/10.1016\/SO140-6736(22)00581-5.","journal-title":"Lancet"},{"key":"1840_CR30","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D\u2019Haens G, et al. Efficacy and safety of Upadacitinib in a randomized trial of patients with Crohn\u2019s disease. Gastroenterology. 2020;158:2123\u201338. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.047.","journal-title":"Gastroenterology"},{"key":"1840_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.030","author":"G D\u2019Haens","year":"2021","unstructured":"D\u2019Haens G, Pan\u00e8s J, Louis E, Lacerda A, Zhou Q, Liu J, et al. Upadacitinib was efficacious and well tolerated over 30 months in patients with Crohn\u2019s disease in the CELEST extension study. Clin Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.030.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1840_CR32","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomized, placebo-controlled trial. Lancet. 2021;397:2372\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8.","journal-title":"Lancet"},{"key":"1840_CR33","unstructured":"Drugs.com FDA approves Rinvoq (Upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis. https:\/\/www.drugs.com\/newdrugs\/rinvoq-upadacitinib-receives-fda-approval-adults-moderately-severely-active-ulcerative-colitis-5800.html. Published March16, 2021. Accessed 1 Sept 2022."},{"issue":"21","key":"1840_CR34","doi-asserted-by":"publisher","first-page":"11322","DOI":"10.3390\/ijms222111322","volume":"22","author":"JW Kim","year":"2021","unstructured":"Kim JW, Kim SY. The era of Janus Kinase inhibitors for inflammatory bowel disease treatment. Int J Mol Sci. 2021;22(21):11322. https:\/\/doi.org\/10.3390\/ijms222111322.","journal-title":"Int J Mol Sci"},{"key":"1840_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, Kuenbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate to severe Crohn\u2019s disease treated with filgotinib (The FITZROY study): results from a phase 2, double blind, randomized, placebo-controlled trial. Lancet. 2017;389:266\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(16)32537-5.","journal-title":"Lancet"},{"key":"1840_CR36","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","volume":"14","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, et al. Development of gut-selective pan-janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicinal programme. J Crohns Colitis. 2020;14:1202\u201313. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa049.","journal-title":"J Crohns Colitis"},{"key":"1840_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326390","author":"NE Burr","year":"2021","unstructured":"Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis; systematic review and network meta-analysis. Gut. 2021. https:\/\/doi.org\/10.1136\/gutjnl-2021-326390.","journal-title":"Gut"},{"key":"1840_CR38","unstructured":"Clinical trials Arena (https:\/\/www.clinicaltrialsarena.com\/news\/theravance-izencitinib-ulcerative-colitis). Theravance\u2019s izencitinib fails in Phase IIb ulcerative colitis trial. August 24, 2021. Accessed 8 Feb 2022."},{"issue":"1","key":"1840_CR39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjab124","volume":"16","author":"S Danese","year":"2022","unstructured":"Danese S, Panaccione R, D\u2019Hanes G, Peyrin-Biroulet L, Scheirber S, Koyabashi S, et al. DOP42 efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study. J Crohns Colitis. 2022;16(1):91\u20132.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"1840_CR40","doi-asserted-by":"publisher","first-page":"e001595","DOI":"10.1136\/rmdopen-2021-001595","volume":"7","author":"G Burmester","year":"2021","unstructured":"Burmester G, Nash P, Sands BE, Papp L, Jones TV, Tan H. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37066 patient-years of tofacinitb exposure. RMD Open. 2021;7(2):e001595. https:\/\/doi.org\/10.1136\/rmdopen-2021-001595.","journal-title":"RMD Open"},{"issue":"12","key":"1840_CR41","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/ibd\/izab135","volume":"27","author":"S Danese","year":"2021","unstructured":"Danese S, Peyrin-Biroulet L. Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise. Inflamm Bowel Dis. 2021;27(12):2023\u201330. https:\/\/doi.org\/10.1093\/ibd\/izab135.","journal-title":"Inflamm Bowel Dis"},{"key":"1840_CR42","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","volume":"14","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, et al. Development of gut-selective Pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme. J Crohn\u2019s Colitis. 2020;14:1202\u201313. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa049.","journal-title":"J. Crohn\u2019s Colitis."},{"key":"1840_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.coph.2020.10.015","volume":"55","author":"F D'Amico","year":"2020","unstructured":"D\u2019Amico F, Peyrin-Biroulet L, Danese S, Fiorino G. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol. 2020;55:141\u201350. https:\/\/doi.org\/10.1016\/j.coph.2020.10.015.","journal-title":"Curr Opin Pharmacol"},{"key":"1840_CR44","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554\u201373. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.001.","journal-title":"Gastroenterology"},{"key":"1840_CR45","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","volume":"17","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, Pan\u00e9s J, D\u2019Haens G, Sands BE, Su C, Moscariello M, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17:1541\u201350. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.035.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1840_CR46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ecco-jcc\/jjaa233","volume":"15","author":"K Winthrop","year":"2021","unstructured":"Winthrop K, Loftus EV Jr, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, et al. Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from ulcerative colitis clinical programme. J Crohns Colitis. 2021;15:914\u201329. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa233.","journal-title":"J Crohns Colitis"},{"key":"1840_CR47","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/apt.16619.Epub2021Oct9","volume":"55","author":"DT Rubin","year":"2022","unstructured":"Rubin DT, Modesto I, Vermeire S, Danese S, Ng SC, Kwok K, et al. Worldwide post marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2022;55:302\u201310. https:\/\/doi.org\/10.1111\/apt.16619.Epub2021Oct9.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1840_CR48","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ecco-jcc\/jjaa233","volume":"15","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Loftus EV Jr, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, et al. Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from the ulcerative colitis clinical programme. J Crohns Colitis. 2021;15(6):914\u201329. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa233. (PMID: 33245746).","journal-title":"J Crohns Colitis"},{"issue":"10","key":"1840_CR49","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, et al. Herpes Zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflam Bowel Dis. 2018;24(10):2258\u201365. https:\/\/doi.org\/10.1093\/ibd\/izy131.","journal-title":"Inflam Bowel Dis."},{"key":"1840_CR50","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/ibd\/izy150","volume":"24","author":"JF Colombel","year":"2018","unstructured":"Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24:2172\u201382. https:\/\/doi.org\/10.1093\/ibd\/izy150.","journal-title":"Inflamm Bowel Dis"},{"key":"1840_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06096-0","author":"W Choi","year":"2022","unstructured":"Choi W, Ahn SM, Kim YG, Lee CK, Yoo B, Hong S. Safety of Jak inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAL inhibitors. Clin Rheumatol. 2022. https:\/\/doi.org\/10.1007\/s10067-022-06096-0.","journal-title":"Clin Rheumatol"},{"key":"1840_CR52","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40266-018-0603-x","volume":"35","author":"YY Syed","year":"2018","unstructured":"Syed YY. Recombinant zoster Vaccine (Shingrix\u00ae): a review in herpes zoster. Drugs Aging. 2018;35:1031\u201340. https:\/\/doi.org\/10.1007\/s40266-018-0603-x.","journal-title":"Drugs Aging"},{"issue":"40","key":"1840_CR53","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S2468-1253(22)00005-X","volume":"7","author":"JL Alexander","year":"2022","unstructured":"Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Seoane RC, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol. 2022;7(40):342\u201352. https:\/\/doi.org\/10.1016\/S2468-1253(22)00005-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1840_CR54","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-11-4","author":"E Liu","year":"2022","unstructured":"Liu E, Aslam N, Nigam GL. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going. Drugs Context. 2022. https:\/\/doi.org\/10.7573\/dic.2021-11-4. (PIMID 35462642).","journal-title":"Drugs Context"},{"issue":"6","key":"1840_CR55","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab05","volume":"15","author":"T Kucharzik","year":"2021","unstructured":"Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, et al. ECCO Guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):879\u2013913. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab05.","journal-title":"J Crohns Colitis"},{"key":"1840_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gastre.2021.01.003","volume":"44","author":"X Calvet","year":"2021","unstructured":"Calvet X, Carpio D, Rodr\u00edguez-Lago I, Garc\u00eda-Vicu\u00f1a R, Barreiro-de-Acosta M, Juanola X, et al. Riesgo de infecci\u00f3n asociado a los inhibidores de las quinasas Janus (JAK) y las terapias biol\u00f3gicas en enfermedad inflamatoria intestinal y artritis reumatoide. Estrategias de prevenci\u00f3n Gastroenterolog\u00eda y Hepatolog\u00eda. 2021;44:587\u201398. https:\/\/doi.org\/10.1016\/j.gastre.2021.01.003.","journal-title":"Estrategias de prevenci\u00f3n Gastroenterolog\u00eda y Hepatolog\u00eda."},{"key":"1840_CR57","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","volume":"159","author":"EJ Brenner","year":"2020","unstructured":"Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, but not TNF antagonist are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159:481-49.e3. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.032.","journal-title":"Gastroenterology"},{"key":"1840_CR58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","volume":"70","author":"RC Ungaro","year":"2021","unstructured":"Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70:725\u201332. https:\/\/doi.org\/10.1136\/gutjnl-2020-322539.","journal-title":"Gut"},{"key":"1840_CR59","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ibd\/izaa303","volume":"27","author":"M Agrawal","year":"2021","unstructured":"Agrawal M, Brenner EJ, Zhang X, Modesto I, Woolcott J, Ungaro RC, et al. Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry. Inflamm Bowel Dis. 2021;27:585\u20139. https:\/\/doi.org\/10.1093\/ibd\/izaa303.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1840_CR60","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","volume":"161","author":"N Khan","year":"2021","unstructured":"Khan N, Mahmud N. Effectiveness of SARS-COV-2 vaccination in a veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure. Gastroenterology. 2021;161(3):827\u201336. https:\/\/doi.org\/10.1053\/j.gastro.2021.05.044.","journal-title":"Gastroenterology"},{"issue":"10","key":"1840_CR61","doi-asserted-by":"publisher","first-page":"e2129639","DOI":"10.1001\/jamanetwork.2021.29639","volume":"4","author":"Z Izadi","year":"2021","unstructured":"Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZN, Yates M, et al. Association between tumor necrosis factors inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4(10):e2129639. https:\/\/doi.org\/10.1001\/jamanetwork.2021.29639.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1840_CR62","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/jgh3.12728","volume":"60","author":"F Alrashed","year":"2022","unstructured":"Alrashed F, Alasfour H, Shebab M. Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: a systematic review and meta-analysis. JGH Open. 2022;60(4):241\u201350. https:\/\/doi.org\/10.1002\/jgh3.12728.","journal-title":"JGH Open"},{"key":"1840_CR63","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, et al. Integrated safety analysis of Filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 16 years. Ann Rheum Dis. 2022;81:184\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221051.","journal-title":"Ann Rheum Dis"},{"key":"1840_CR64","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","volume":"17","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, Pan\u00e9s J, Dhaens GR, Sands BE, Su C, Moscariello M, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17:1541\u201350. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.035.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1840_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","volume":"18","author":"BE Sands","year":"2020","unstructured":"Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, et al. Tofacinitib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(1):123-132.e3. https:\/\/doi.org\/10.1016\/j.cgh.2019.04.059.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1840_CR66","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","volume":"41","author":"L Na","year":"2022","unstructured":"Na L, Zhong-Ping G, Shuang-Qing D, Xiao-Hong Z, Hui L, Xiu-Fang L. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. Clin Rheumatol. 2022;41(3):677\u201388. https:\/\/doi.org\/10.1007\/s10067-021-06003-z.","journal-title":"Clin Rheumatol"},{"key":"1840_CR67","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/ibd\/izaa199","volume":"27","author":"GR Lichtenstein","year":"2021","unstructured":"Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancy (excluding nonmelanoma skin cancer) events across the ulcerative colitis clinical program. Inflam Bowel Dis. 2021;27:816\u201325. https:\/\/doi.org\/10.1093\/ibd\/izaa199.","journal-title":"Inflam Bowel Dis"},{"key":"1840_CR68","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ibd\/izab056","volume":"28","author":"BE Sands","year":"2022","unstructured":"Sands BE, Long MD, Reinisch W, Pan\u00e9s J, Loftus EV Jr, Nduaka CI, et al. Tofacitinib for the treatment of ulcerative colitis: analysis of nonmelanoma skin cancer rates from the ulcerative colitis clinical program. Inflamm Bowel Dis. 2022;28:234\u201345. https:\/\/doi.org\/10.1093\/ibd\/izab056.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1840_CR69","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/nnrheumdis-2014-205847","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831\u201341. https:\/\/doi.org\/10.1136\/nnrheumdis-2014-205847.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1840_CR70","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. Psoriasis and psoriatic arthritis development programmes and from real world data. Ann Rheum Dis. 2020;79(11):1400\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216761.","journal-title":"Ann Rheum Dis"},{"key":"1840_CR71","unstructured":"US Food and Drug Administration; Drug Safety Communications. Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate. https:\/\/www.fda.gov\/media\/120485\/download. Accessed 30 Aug 2022."},{"key":"1840_CR72","unstructured":"European Medicines Agency. Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis_en.pdf. Accessed 30 July 2022."},{"key":"1840_CR73","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real world data. Ann Rheum Dis. 2020;79:1400\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216761.","journal-title":"Ann Rheum Dis"},{"key":"1840_CR74","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","volume":"60","author":"B Clarke","year":"2021","unstructured":"Clarke B, Yates M, Adas M, Bechman K, Galloway J. The safety of JAK-1 inhibitors. Reumatology. 2021;60:ii24\u201330. https:\/\/doi.org\/10.1093\/rheumatology\/keaa895.","journal-title":"Reumatology"},{"key":"1840_CR75","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2383","volume":"10","author":"A Naranjo","year":"2008","unstructured":"Naranjo A, Sokka T, Descalzo MA, Calvo-Al\u00e9n J, H\u00f8rslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10:R30. https:\/\/doi.org\/10.1186\/ar2383.","journal-title":"Arthritis Res Ther"},{"key":"1840_CR76","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"1840_CR77","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19895492","author":"W Xie","year":"2019","unstructured":"Xie W, Xiao S, Huang Y, Sun X, Zhang Z. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2019. https:\/\/doi.org\/10.1177\/1759720X19895492.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"1840_CR78","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2011","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2011;80(3):304\u201311. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510.","journal-title":"Ann Rheum Dis"},{"key":"1840_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756284819848631","volume":"12","author":"F D\u2019Amico","year":"2019","unstructured":"D\u2019Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danse S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Ther Adv Gastroenterol. 2019;12:1\u201310. https:\/\/doi.org\/10.1177\/1756284819848631.","journal-title":"Ther Adv Gastroenterol"},{"key":"1840_CR80","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/IBD\/izz037","volume":"25","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernaslo N, Boland B, Chambers C, Dubinsky M, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Inflamm Bowel Dis. 2019;25:627\u201341. https:\/\/doi.org\/10.1093\/IBD\/izz037.","journal-title":"Inflamm Bowel Dis"},{"key":"1840_CR81","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/ibd\/izy160","volume":"24","author":"U Mahadevan","year":"2018","unstructured":"Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, et al. Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24:2494\u2013500. https:\/\/doi.org\/10.1093\/ibd\/izy160.","journal-title":"Inflamm Bowel Dis"},{"key":"1840_CR82","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/ibd\/izz037","volume":"25","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Inflamm Bowel Dis. 2019;25:627\u201341. https:\/\/doi.org\/10.1093\/ibd\/izz037.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"1840_CR83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12876022022987","volume":"22","author":"MV Chiorian","year":"2022","unstructured":"Chiorian MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, et al. Real world characteristics, treatment experiences and corticosteroid utilization of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol. 2022;22(1):356. https:\/\/doi.org\/10.1186\/s12876022022987.","journal-title":"BMC Gastroenterol"},{"key":"1840_CR84","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12:7140. https:\/\/doi.org\/10.1038\/s41598-022-10777-w.","journal-title":"Sci Rep"},{"issue":"10","key":"1840_CR85","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","volume":"12","author":"BE Sands","year":"2018","unstructured":"Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, et al. Peficitinib, an Oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study. J Crohns Colitis. 2018;12(10):1158\u201369. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy085.","journal-title":"J Crohns Colitis"},{"key":"1840_CR86","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023 (In Press).","DOI":"10.1016\/j.cgh.2022.12.029"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01840-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T01:04:25Z","timestamp":1679187865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01840-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01840-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"29 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by SCELC, Statewide California Electronic Library Consortium","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PN has been a consultant for Janssen and Ferring, RQ has been a consultant for Jansen and AJY has been a consultant for Takeda, Pfizer, Bristol Myers Squibb, Arena pharmaceuticals, Prometheus Labs and Procise.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed equally to this review with the conception and design of the study, literature review and analysis, drafting and critical revision and editing, and approval of the final version","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}